Equities Analysts Issue Forecasts for EYPT FY2025 Earnings

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Eyepoint Pharmaceuticals in a research note issued to investors on Tuesday, November 25th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings per share of ($3.15) for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($2.13) per share. Cantor Fitzgerald also issued estimates for Eyepoint Pharmaceuticals’ FY2026 earnings at ($2.35) EPS.

Other analysts have also issued reports about the company. Mizuho set a $28.00 price objective on Eyepoint Pharmaceuticals in a research note on Monday, October 20th. Chardan Capital reissued a “buy” rating and issued a $27.00 target price on shares of Eyepoint Pharmaceuticals in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright upped their price objective on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Finally, Royal Bank Of Canada raised their target price on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.00.

Eyepoint Pharmaceuticals Stock Performance

Shares of EYPT opened at $14.83 on Thursday. Eyepoint Pharmaceuticals has a 52-week low of $3.91 and a 52-week high of $14.96. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -5.53 and a beta of 1.85. The business’s fifty day moving average is $12.89 and its 200-day moving average is $10.97.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. The firm had revenue of $0.97 million for the quarter, compared to analyst estimates of $3.33 million.

Institutional Trading of Eyepoint Pharmaceuticals

Several institutional investors have recently modified their holdings of EYPT. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Eyepoint Pharmaceuticals by 62.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,571 shares of the company’s stock worth $122,000 after purchasing an additional 8,676 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of Eyepoint Pharmaceuticals by 10.2% in the first quarter. Federated Hermes Inc. now owns 4,085,580 shares of the company’s stock valued at $22,144,000 after buying an additional 378,135 shares during the period. XTX Topco Ltd bought a new position in shares of Eyepoint Pharmaceuticals during the first quarter worth about $237,000. Vanguard Group Inc. lifted its stake in shares of Eyepoint Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company’s stock worth $20,782,000 after acquiring an additional 31,141 shares during the period. Finally, Deutsche Bank AG boosted its holdings in Eyepoint Pharmaceuticals by 67.5% in the first quarter. Deutsche Bank AG now owns 357,442 shares of the company’s stock valued at $1,937,000 after acquiring an additional 144,060 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.